September 16, 2014 (Shareholders Foundation) - An investigation on behalf of investors of Amarin Corporation plc (ADR) (NASDAQ:AMRN) shares, who purchased NASDAQ:AMRN shares on the July 10, 2013 public offering, over potential securities laws violations was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Amarin Corporation plc (ADR) (NASDAQ:AMRN) on the July 10, 2013 public offering concerning whether certain statements regarding Amarins business, its prospects and its operations were materially false and misleading at the time they were made.

On October 11, 2013 the U.S. Food and Drug Administration (FDA) released its briefing documents for the October 16, 2013 advisory committee review of Amarin's application seeking expanded approval for the use of its fish oil-based drug, Vascepa, in the treatment of adult patients with high triglycerides with mixed dyslipidemia.

On October 16, 2013, Amarin Corporation plc announced that the FDA Endocrinologic and Metabolic Drugs Advisory Committee has voted 9 to 2 against approval of Vascepa (icosapent ethyl) capsules for use as an adjunct to diet and exercise and in combination with a statin in the treatment of adult patients with high triglycerides (TG 200-499 mg/dL) with mixed dyslipidemia and coronary heart disease (CHD) or a CHD risk equivalent (the ANCHOR indication) based on the information presented at the committee meeting on October 16, 2013.